REFERENCES
1. Schizophrenia. Fact sheet on schizophrenia: key facts, symptoms, causes of schizophrenia, WHO; 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia [Last accessed on 15 June 2023].
2. Kane JM, Agid O, Baldwin ML, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry 2019;80:18com12123.
3. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012;201:481-5.
4. Gören JL, Rose AJ, Smith EG, Ney JP. The business case for expanded clozapine utilization. Psychiatr Serv 2016;67:1197-205.
6. Ernst CL, Goldberg JF. Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 2004;12:14-41.
7. Verma M, Grover S, Chakrabarti S. Effectiveness of clozapine on quality of life and functioning in patients with treatment-resistant schizophrenia. Nord J Psychiatry 2021;75:135-44.
8. Thien K, O’Donoghue B. Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: A literature review. Early Interv Psychiatry 2019;13:18-23.
9. Whiskey E, Barnard A, Oloyede E, Dzahini O, Taylor DM, Shergill SS. An evaluation of the variation and underuse of clozapine in the United Kingdom. Acta Psychiatr Scand 2021;143:339-47.
10. Bogers JP, Schulte PF, Van Dijk D, Bakker B, Cohen D. Clozapine underutilization in the treatment of schizophrenia: how can clozapine prescription rates be improved? J Clin Psychopharmacol 2016;36:109-11.
11. Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 2014;14:102.
12. Verdoux H, Quiles C, Bachmann CJ, Siskind D. Prescriber and institutional barriers and facilitators of clozapine use: a systematic review. Schizophr Res 2018;201:10-9.
13. Verdoux H, Quiles C. Educational needs and psychoeducation interventions in clozapine users: a narrative review. Acta Psychiatr Scand 2020;142:96-108.
14. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156:990-9.
15. Baig AI, Bazargan-Hejazi S, Ebrahim G, Rodriguez-Lara J. Clozapine prescribing barriers in the management of treatment-resistant schizophrenia: a systematic review. Medicine 2021;100:e27694.
16. Waserman J, Criollo M. Subjective experiences of clozapine treatment by patients with chronic schizophrenia. Psychiatr Serv 2000;51:666-8.
17. Citrome L, McEvoy JP, Saklad SR. Guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychoses 2016;10:163-77.
18. Chathoth V, Ramamurthy P, Solomon S. Clozapine-induced insulin-resistant hyperglycemia in a diabetic patient. Indian J Psychol Med 2018;40:375-7.
19. Myles N, Myles H, Xia S, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand 2018;138:101-9.
20. Li XH, Zhong XM, Lu L, et al. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychol Med 2020;50:583-94.
21. Leon J, Sanz EJ, De Las Cuevas C. Data from the world health organization’s pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions. Schizophr Bull 2020;46:1-3.
22. Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 2012;6:134-44.
23. Farooq S, Taylor M. Clozapine: dangerous orphan or neglected friend? Br J Psychiatry 2011;198:247-9.
24. Farooq S, Choudry A, Cohen D, Naeem F, Ayub M. Barriers to using clozapine in treatment-resistant schizophrenia: systematic review. BJPsych Bull 2019;43:8-16.
25. Gee S, Vergunst F, Howes O, Taylor D. Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand 2014;130:16-24.
26. Shah P, Iwata Y, Plitman E, et al. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review. Psychiatry Res 2018;268:114-22.
27. Schulte P. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother 2006;40:683-8.
28. Girardin FR, Poncet A, Blondon M, et al. Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis. Lancet Psychiatry 2014;1:55-62.
29. Fabrazzo M, Prisco V, Sampogna G, et al. Clozapine versus other antipsychotics during the first 18 weeks of treatment: A retrospective study on risk factor increase of blood dyscrasias. Psychiatry Res 2017;256:275-82.
30. Üçok A, Çikrikçili U, Karabulut S, et al. Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. Int Clin Psychopharmacol 2015;30:290-5.
31. John AP, Ko EKF, Dominic A. Delayed initiation of clozapine continues to be a substantial clinical concern. Can J Psychiatry 2018;63:526-31.
32. Varghese M T, Jyothi KS, Shaji KS, Rita Venugopal L. Delaying clozapine: how long is too long? Gen Psychiatr 2020;33:e100172.
33. Verbelen M, Lewis CM. How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis? Pharmacogenomics 2015;16:915-7.
34. Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry 2017;62:772-7.
35. Shah P, Iwata Y, Brown EE, et al. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. Eur Arch Psychiatry Clin Neurosci 2020;270:11-22.
36. Meltzer HY. Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin 1997;14:1-20.
37. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
38. Islam F, Hain D, Lewis D, et al. Pharmacogenomics of clozapine-induced agranulocytosis: a systematic review and meta-analysis. Pharmacogenomics J 2022;22:230-40.
39. Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990;47:945-8.
40. Corzo D, Yunis JJ, Salazar M, et al. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 1995;86:3835-40.
41. Yunis JJ, Corzo D, Salazar M, Lieberman JA, Howard A, Yunis EJ. HLA associations in clozapine-induced agranulocytosis. Blood 1995;86:1177-83.
42. Turbay D, Lieberman J, Alper CA, et al. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood 1997;89:4167-74.
43. Amar A, Segman RH, Shtrussberg S, et al. An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201. Int J Neuropsychopharmacol 1998;1:41-4.
44. Valevski A, Klein T, Gazit E, et al. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur J Immunogenet 1998;25:11-3.
45. Ostrousky O, Meged S, Loewenthal R, et al. NQO2 gene is associated with clozapine-induced agranulocytosis. Tissue Antigens 2003;62:483-91.
46. Lahdelma L, Ahokas A, Andersson LC, et al. Mitchell B. Balter award. human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. J Clin Psychopharmacol 2001;21:4-7.
47. Dettling M, Schaub RT, Mueller-Oerlinghausen B, Roots I, Cascorbi I. Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics 2001;11:135-41.
48. Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R. Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J 2007;7:325-32.
49. van der Weide K, Loovers H, Pondman K, et al. Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population. Pharmacogenomics J 2017;17:471-8.
50. Athanasiou MC, Dettling M, Cascorbi I, et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 2011;72:458-63.
51. Legge SE, Hamshere ML, Ripke S, et al. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Mol Psychiatry 2017;22:1502-8.
52. Goldstein JI, Jarskog LF, Hilliard C, et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun 2014;5:4757.
53. Saito T, Ikeda M, Mushiroda T, et al. Pharmacogenomic study of clozapine-induced agranulocytosis/granulocytopenia in a Japanese population. Biol Psychiatry 2016;80:636-42.
54. Eap CB, Bender S, Sirot EJ, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 2004;24:214-9.
55. Balibey H, Basoglu C, Lundgren S, et al. CYP1A2*1F polymorphism decreases clinical response to clozapine in patients with schizophrenia. Bull Clin Psychopharm 2011;21:93-9.
56. de Brito RB, de Carvalho Araújo L, Diniz MJA, et al. The CYP1A2 -163C > A polymorphism is associated with super-refractory schizophrenia. Schizophr Res 2015;169:502-3.
57. Piatkov I, Caetano D, Assur Y, et al. CYP2C19*17 protects against metabolic complications of clozapine treatment. World J Biol Psychiatry 2017;18:521-7.
58. Lee ST, Ryu S, Kim SR, et al. Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. J Clin Psychopharmacol 2012;32:441-8.
59. Shaikh S, Collier DA, Sham PC, et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet 1996;97:714-9.
60. Scharfetter J, Chaudhry HR, Hornik K, et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients. Eur Neuropsychopharmacol 1999;10:17-20.
61. Hwang R, Zai C, Tiwari A, et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J 2010;10:200-18.
62. Huang E, Maciukiewicz M, Zai CC, et al. Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response. Pharmacogenomics 2016;17:103-9.
63. Hwang R, Shinkai T, Deluca V, et al. Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment. Eur Neuropsychopharmacol 2006;16:248-59.
64. Hwang R, Shinkai T, De Luca V, et al. Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology 2005;181:179-87.
65. Malhotra A. Allelic variation in the promoter region of the dopamine D-2 receptor gene and clozapine response. In: Schizophrenia research. Amsterdam, Netherlands: Elsevier Science B.V.; 1999.
66. Hwang R, Tiwari AK, Zai CC, et al. Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration. Prog Neuropsychopharmacol Biol Psychiatry 2012;37:62-75.
67. Zhao AL, Zhao JP, Zhang YH, Tang BS, Liu ZN, Cheng JD. [Distribution of genotype and allele frequencies of dopamine D4 receptor gene 48 bp variable number tandem repeat polymorphism in Chinese Han population in Hunan]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2005;22:470-2.
68. Hwang R, Shinkai T, De Luca V, et al. Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol 2007;21:718-27.
69. Potkin SG, Basile VS, Jin Y, et al. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry 2003;8:109-13.
70. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007;90:86-96.
71. Xu M, Xing Q, Li S, et al. Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1026-32.
72. Arranz MJ, Collier DA, Munro J, et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett 1996;217:177-8.
73. Arranz MJ, Munro J, Owen MJ, et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 1998;3:61-6.
74. Masellis M, Basile V, Meltzer HY, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998;19:123-32.
75. Arranz M, Collier D, Sodhi M, et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995;346:281-2.
76. Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics 2010;20:274-6.
77. Rajkumar AP, Poonkuzhali B, Kuruvilla A, Srivastava A, Jacob M, Jacob KS. Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia. Psychopharmacology 2012;224:441-9.
78. Kohlrausch FB, Salatino-Oliveira A, Gama CS, Lobato MI, Belmonte-de-Abreu P, Hutz MH. Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics. J Psychiatr Res 2010;44:1158-62.
79. Yu YW, Tsai SJ, Lin CH, Hsu CP, Yang KH, Hong CJ. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport 1999;10:1231-3.
80. Sodhi MS, Arranz MJ, Curtis D, et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995;7:169-72.
81. Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet 2000;355:1615-6.
82. Hwang R, Souza RP, Tiwari AK, et al. Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. Pharmacogenomics 2011;12:277-91.
83. Bosia M, Lorenzi C, Pirovano A, et al. COMT Val158Met and 5-HT1A-R-1019 C/G polymorphisms: effects on the negative symptom response to clozapine. Pharmacogenomics 2015;16:35-44.
84. Rajagopal VM, Rajkumar AP, Jacob KS, Jacob M. Gene-gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia. Pharmacogenet Genomics 2018;28:31-5.
85. Xu M, Lin Z. Genetic influences of dopamine transport gene on alcohol dependence: a pooled analysis of 13 studies with 2483 cases and 1753 controls. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1255-60.
86. Yu YW, Tsai SJ, Yang KH, Lin CH, Chen MC, Hong CJ. Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine. Neuropsychobiology 2001;43:79-82.
87. Brandl EJ, Lett TA, Chowdhury NI, et al. The role of the ITIH3 rs2535629 variant in antipsychotic response. Schizophr Res 2016;176:131-5.
88. Ikeda M, Yoshimura R, Hashimoto R, et al. Genetic overlap between antipsychotic response and susceptibility to schizophrenia. J Clin Psychopharmacol 2015;35:85-8.
89. Adkins DE, Aberg K, McClay JL, et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 2011;16:321-32.
90. With SAJ, Pulit SL, Staal WG, Kahn RS, Ophoff RA. More than 25 years of genetic studies of clozapine-induced agranulocytosis. Pharmacogenomics J 2017;17:304-11.
91. Lally J, Malik S, Whiskey E, et al. Clozapine-associated agranulocytosis treatment with granulocyte colony-stimulating factor/granulocyte-macrophage colony-stimulating factor: a systematic review. J Clin Psychopharmacol 2017;37:441-6.
92. la Chapelle A, Kari C, Nurminen M, Hernberg S. Clozapine-induced agranulocytosis. A genetic and epidemiologic study. Hum Genet 1977;37:183-94.
93. Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P. Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatr Scand 1977;56:241-8.
94. Clark SR, Warren NS, Kim G, et al. Elevated clozapine levels associated with infection: a systematic review. Schizophr Res 2018;192:50-6.
95. Ruan CJ, Zhen XY, Ge XL, et al. Pneumonia can cause clozapine intoxication: a case report. Psychosomatics 2017;58:652-6.
96. Wagner A, Shad MU. Relationship between clozapine levels and acute inflammatory stress. Prim Care Companion CNS Disord 2020;22:19br02586.
97. Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol 2000;56:585-9.
98. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003;28:99-112.
99. Ruan CJ, de Leon J. Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine? Pharmacogenomics 2020;21:369-73.
100. Buur-Rasmussen B, Brøsen K. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol 1999;9:453-9.
101. Dettling M, Sachse C, Müller-Oerlinghausen B, et al. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry 2000;33:218-20.
102. Røge R, Møller BK, Andersen CR, Correll CU, Nielsen J. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res 2012;140:204-13.
103. Taylor D, Vallianatou K, Whiskey E, Dzahini O, MacCabe J. Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis. Schizophrenia 2022;8:21.
104. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12760 clozapine recipients in the UK and Ireland. Br J Psychiatry 1999;175:576-80.
105. Riecher-Rössler A. [50 years after Manfred Bleuler. what do we know today about late-onset schizophrenia(s)?]. Nervenarzt 1997;68:159-70.
106. Dettling M, Cascorbi I, Roots I, Mueller-Oerlinghausen B. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample. Arch Gen Psychiatry 2001;58:93-4.
107. Deliliers G. Blood dyscrasias in clozapine-treated patients in Italy. Haematologica 2000;85:233-7.
108. Stübner S, Grohmann R, Engel R, et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 2004;37 Suppl 1:S70-8.
109. Demler TL, Morabito NE, Meyer CE, Opler L. Maximizing clozapine utilization while minimizing blood dyscrasias: evaluation of patient demographics and severity of events. Int Clin Psychopharmacol 2016;31:76-83.
110. Hollingworth SA, Winckel K, Saiepour N, Wheeler AJ, Myles N, Siskind D. Correction to: clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993-2014. Psychopharmacology 2018;235:2193.
111. Tunsirimas N, Pariwatcharakul P, Choovanichvong S, Ratta-Apha W. Clozapine-induced agranulocytosis and leukopenia: incidence, associated factors, and rate of hematologic adverse-effects monitoring in psychiatric out-patient services in Thailand. Asian J Psychiatr 2019;41:13-6.
112. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329:162-7.
113. Wellesley Wesley E, Patel I, Kadra-Scalzo G, et al. Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register. Schizophr Res 2021;232:68-76.
114. Horáček J, Libiger J, Höschl C, Borzova K, Hendrychová I. Clozapine-induced concordant agranulocytosis in monozygotic twins. Int J Psychiatry Clin Pract 2001;5:71-3.
115. Yağcıoğlu AE, İlhan BÇ, Göktaş MT, Babaoğlu MO, Uz E, Yazıcı MK. Agranulocytosis related to clozapine in monozygotic twins and association with allelic variants of multidrug resistance gene MDR1. J Clin Psychopharmacol 2011;31:247-9.
116. Osafo-Addo AD, Koram KA, Oduro AR, Wilson M, Hodgson A, Rogers WO. HLA-DRB1*04 allele is associated with severe malaria in northern Ghana. Am J Trop Med Hyg 2008;78:251-5.
117. Park HW, Kim DK, Kim SH, et al. Efficacy of the HLA-B*58:01 screening test in preventing allopurinol-induced severe cutaneous adverse reactions in patients with chronic renal insufficiency-a prospective study. J Allergy Clin Immunol Pract 2019;7:1271-6.
118. Wang Q, Sun S, Xie M, Zhao K, Li X, Zhao Z. Association between the HLA-B alleles and carbamazepine-induced SJS/TEN: a meta-analysis. Epilepsy Res 2017;135:19-28.
119. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004;5:203-11.
120. Capule F, Tragulpiankit P, Mahasirimongkol S, et al. Association of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients. Pharmacogenomics J 2020;20:533-41.
121. Verbelen M, Collier DA, Cohen D, MacCabe JH, Lewis CM. Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis. Pharmacogenomics J 2015;15:461-6.
122. Grover S, Kukreti R. HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet Genomics 2014;24:94-112.
124. Konte B, Walters JTR, Rujescu D, et al. HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry. Transl Psychiatry 2021;11:214.
125. Saito T, Ikeda M, Hashimoto R, et al. Transethnic replication study to assess the association between clozapine-induced agranulocytosis/granulocytopenia and genes at 12p12.2 in a Japanese population. Biol Psychiatry 2017;82:e9-10.
126. Chen J, Yang P, Zhang Q, et al. Genetic risk of clozapine-induced leukopenia and neutropenia: a genome-wide association study. Transl Psychiatry 2021;11:343.
127. Mosyagin I, Dettling M, Roots I, Mueller-Oerlinghausen B, Cascorbi I. Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol 2004;24:613-7.
128. Legge SE, Pardiñas AF, Helthuis M, et al. A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. Mol Psychiatry 2019;24:328-37.
129. Okhuijsen-Pfeifer C, Sterk AY, Horn IM, Terstappen J, Kahn RS, Luykx JJ. Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: A systematic review and meta-analysis. Neurosci Biobehav Rev 2020;111:246-52.
130. Comacchio C, Dusi N, Lasalvia A. Successful use of single doses of granulocyte-colony stimulating factor (G-CSF) in the treatment of late-onset agranulocytosis associated with clozapine in a patient with treatment-resistant schizophrenia: a case report. J Clin Psychopharmacol 2016;36:173-4.
131. Freeman GM Jr, Martin BA, Hu RJ. G-CSF dosing to prevent recurrent clozapine-induced agranulocytosis. Am J Psychiatry 2016;173:643.
132. Lally J, Malik S, Krivoy A, et al. The use of granulocyte colony-stimulating factor in clozapine rechallenge: a systematic review. J Clin Psychopharmacol 2017;37:600-4.
133. Blier P, Slater S, Measham T, Koch M, Wiviott G. Lithium and clozapine-induced neutropenia/agranulocytosis. Int Clin Psychopharmacol 1998;13:137-40.
134. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007;12:707-47.
135. Shad MU. Clozapine toxicity: a discussion of pharmacokinetic factors. Asian J Psychiatr 2008;1:47-9.
136. Shad MU, Felzien E, Roy K, Sethi S. How to identify and manage non-response to clozapine? Asian J Psychiatr 2019;45:50-2.
137. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008;9:410-8.
139. Rajkumar AP, Poonkuzhali B, Kuruvilla A, Srivastava A, Jacob M, Jacob KS. Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia. Acta Neuropsychiatr 2013;25:2-11.
140. Piatkov I, Caetano D, Assur Y, et al. ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine. Pharmgenomics Pers Med 2017;10:235-42.
141. Xing Q, Gao R, Li H, et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006;7:987-93.
142. Zhao AL, Zhao JP, Zhang YH, Xue ZM, Chen JD, Chen XG. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci 2005;115:1539-47.
143. Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010;167:763-72.
144. Gressier F, Porcelli S, Calati R, Serretti A. Pharmacogenetics of clozapine response and induced weight gain: a comprehensive review and meta-analysis. Eur Neuropsychopharmacol 2016;26:163-85.
145. Schäfer M, Rujescu D, Giegling I, et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D2 receptor gene. Am J Psychiatry 2001;158:802-4.
146. Suzuki A, Kondo T, Otani K, et al. Association of the TaqI A polymorphism of the dopamine D2 receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry 2001;158:1714-6.
147. Vijayan NN, Bhaskaran S, Koshy LV, et al. Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population. Behav Brain Funct 2007;3:34.
148. Dahmen N, Müller MJ, Germeyer S, et al. Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients. Schizophr Res 2001;49:223-5.
149. Samanaite R, Gillespie A, Sendt KV, McQueen G, MacCabe JH, Egerton A. Biological predictors of clozapine response: a systematic review. Front Psychiatry 2018;9:327.
150. Numata S, Umehara H, Ohmori T, Hashimoto R. Clozapine pharmacogenetic studies in schizophrenia: efficacy and agranulocytosis. Front Pharmacol 2018;9:1049.
151. Anttila S, Illi A, Kampman O, Mattila KM, Lehtimäki T, Leinonen E. Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics 2004;14:303-7.
152. Huang E, Zai CC, Lisoway A, et al. Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis. Int J Neuropsychopharmacol 2016;19:pyv132.
153. Molero P, Ortuño F, Zalacain M, Patiño-García A. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J 2007;7:418-26.
154. Weickert TW, Goldberg TE, Mishara A, et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004;56:677-82.
155. Szekeres G, Kéri S, Juhász A, et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004;124B:1-5.
156. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994;55 Suppl B:47-52.
157. Arranz MJ, Munro J, Sham P, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998;32:93-9.
158. Joober R, Benkelfat C, Brisebois K, et al. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J Psychiatry Neurosci 1999;24:141-6.
159. Arranz MJ, Li T, Munro J, et al. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics 1998;8:481-4.
160. Hamdani N, Bonnière M, Adès J, Hamon M, Boni C, Gorwood P. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics. Neurosci Lett 2005;377:69-74.
161. Benmessaoud D, Hamdani N, Boni C, et al. Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics. BMC Psychiatry 2008;8:40.
162. Mauri MC, Paletta S, Maffini M, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J 2014;13:1163-91.
163. Birkett JT, Arranz MJ, Munro J, Osbourn S, Kerwin RW, Collier DA. Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuroreport 2000;11:2017-20.
164. Gutiérrez B, Arranz MJ, Huezo-Diaz P, et al. Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophr Res 2002;58:93-7.
165. Wang L, Fang C, Zhang A, et al. The -1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol 2008;22:904-9.
166. Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry 2006;163:1826-9.
167. Mössner R, Schuhmacher A, Kühn KU, et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics 2009;19:91-4.
168. Masellis M, Basile VS, Meltzer HY, et al. Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophr Res 2001;47:49-58.
169. Schumacher J, Schulze TG, Wienker TF, Rietschel M, Nöthen MM. Pharmacogenetics of the clozapine response. Lancet 2000;356:506-7.
170. Tsai SJ, Hong CJ, Yu YW, et al. Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response. Schizophr Res 2000;44:177-81.
171. Arranz MJ, Bolonna AA, Munro J, Curtis CJ, Collier DA, Kerwin RW. The serotonin transporter and clozapine response. Mol Psychiatry 2000;5:124-5.
172. Lee HY, Kim DJ, Lee HJ, Choi JE, Kim YK. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:276-80.
173. Vázquez-Bourgon J, Arranz MJ, Mata I, et al. Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry Res 2010;175:189-94.
174. Xu Q, Wu X, Li M, et al. Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population. Pharmacogenomics J 2016;16:357-65.
175. Ruderfer DM, Charney AW, Readhead B, et al. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. Lancet Psychiatry 2016;3:350-7.
176. Gardner KR, Brennan FX, Scott R, Lombard J. The potential utility of pharmacogenetic testing in psychiatry. Psychiatry J 2014;2014:730956.
177. Eum S, Lee AM, Bishop JR. Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues Clin Neurosci 2016;18:323-37.
